Loading company
Adlai Nortye Group Ltd.
ANL · Nasdaq · ·
$15.71+0.9%Sep 29 close
- 1M
- +13.6%
- 6M
- +137.6%
- 1Y
- +773.1%
ANL · Nasdaq · ·
$15.71+0.9%Sep 29 close
From the company’s own 6-K filing.
“We continue to execute well across our pipeline, with initial clinical data on track for both of our pan-RAS(ON) inhibitor-based assets in 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site. 2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells. 4
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Adlai Nortye Group Ltd. filed on August 14, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Adlai Nortye Group Ltd. has no earnings call transcript available.